β-Catenin–Facilitated Glycolytic Reprogramming Fuels TNBC Progression: Therapeutic Blockade with XAV939
Technology in Cancer Research & Treatment · 2026
DOI: 10.1177/15330338261425407 ↗Kurz gefasst
Fachartikel in der Zeitschrift Technology in Cancer Research & Treatment, 2026. Verfasst von Sheikh Mohammad Umar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology (Lab), Dr BRA IRCH, AIIMS, Ansari Nagar, New Delhi, India. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, beta Catenin, Glycolysis, Heterocyclic Compounds, 3-Ring. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Council of Scientific and Industrial Research (CSIR), India, DST SERB ECR, AIIMS.
Abstract (Originalsprache)
Introduction
Glycolytic phenotype positively supports cancer cell migration and metastasis in various cancers including Triple negative breast cancers (TNBCs). In-depth understanding of molecular pathways associated with increased aerobic glycolysis in TNBCs could provide key insights into the drivers of TNBC progression. Methods β-catenin and glycolytic proteins (PFKP, LDHA, MCT1) were assessed by Immunohistochemistry (IHC) in TNBC patients (n = 98), with prognostic value evaluated by Kaplan-Meier and Cox regression. In vitro , the β-catenin inhibitor ie, XAV939 was tested for suppressing β-catenin-driven aerobic glycolysis in TNBC models using MTT for proliferation, Western blotting for protein expression, and wound healing, droplet invasion, and colony formation assays for physiological changes. Results β-catenin and glycolytic markers (PFKP, LDHA, MCT1) were overexpressed in >50% of TNBCs. Kaplan-Meier and Cox regression analyses showed that combined expression of β-catenin with glycolytic markers correlated with reduced survival. In vitro , XAV939 suppressed β-catenin-driven aerobic glycolysis in TNBC cells, downregulating β-catenin and glycolytic proteins, reducing glycolytic activity, and impairing aggressive phenotypes (proliferation, migration, invasion, clonogenicity).
Conclusion
Overall, our results highlight the crucial role of β-catenin in controlling aerobic glycolysis via regulation of key glycolytic proteins, thereby positively driving the progression and metastasis of TNBCs. Additionally, our data strongly establish that XAV939 effectively inhibits glycolytic phenotype, thereby suggesting its therapeutic potential in TNBC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology (Lab), Dr BRA IRCH, AIIMS, Ansari Nagar, New Delhi, India.
- Department of Pathology, AIIMS, Ansari Nagar, New Delhi, India.
- Department of Medical Oncology, Dr BRA IRCH, AIIMS, Ansari Nagar, New Delhi, India.
- Department of Surgical Oncology, Dr BRA IRCH, AIIMS, Ansari Nagar, New Delhi, India.
- Department of Biostatistics, AIIMS, Ansari Nagar, New Delhi, India.
ORCID-Profile: Chandra Prakash Prasad
Förderung
- Council of Scientific and Industrial Research (CSIR), India
- DST SERB ECR
- AIIMS
Zitieren
APA
Umar, S. M., Kahol, S., Mathur, S. R., Gogia, A., Deo, S. V. S., Pandey, S., & Prasad, C. P. (2026). β-Catenin–Facilitated Glycolytic Reprogramming Fuels TNBC Progression: Therapeutic Blockade with XAV939. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338261425407
Vancouver
Umar SM, Kahol S, Mathur SR, Gogia A, Deo SVS, Pandey S, et al. β-Catenin–Facilitated Glycolytic Reprogramming Fuels TNBC Progression: Therapeutic Blockade with XAV939. Technology in Cancer Research & Treatment. 2026. doi:10.1177/15330338261425407
BibTeX
@article{Umar2026,
author = {Umar, Sheikh Mohammad and Kahol, Shruti and Mathur, Sandeep R and Gogia, Ajay and Deo, S V S and Pandey, Shivam and Prasad, Chandra Prakash},
title = {β-Catenin–Facilitated Glycolytic Reprogramming Fuels TNBC Progression: Therapeutic Blockade with XAV939},
journal = {Technology in Cancer Research & Treatment},
year = {2026},
doi = {10.1177/15330338261425407}
}
EUVIMED